Analyst/Investor Presentation

Corona Remedies reported FY26 revenue of INR 1,403.2 Cr, up 17.3% Y-o-Y, with adjusted PAT of INR 199.4 Cr growing 33.4%. Q4FY26 revenue was INR 353.1 Cr (+20.2%). EBITDA margin expanded to 20.9% in FY26 (+85 bps) driven by chronic portfolio shift. The company acquired Wokadine from Dr. Reddy's (entry into Rs 6,481 Cr Povidone Iodine market) and 7 brands from Bayer Zydus to strengthen its infertility segment, both funded from internal accruals. Bhayla facility received EAEU-GMP certification opening access to ~USD 25 billion Eurasian markets. Capacity expanded by 400 Mn tablets. Chronic therapies now contribute 71.9% of FY26 revenue vs 28.1% acute, reflecting a strategic portfolio shift. Return ratios are strong: ROE 29.2%, ROCE 40.8%, OCF/EBITDA 78.2%.